Core Insights - Nyxoah has appointed John Landry as Chief Financial Officer, effective November 4, 2024, to enhance its focus on the U.S. market [1][3] - Loïc Moreau, the current CFO, will transition to the newly created role of President International, leading global expansion efforts [3][4] Company Overview - Nyxoah is a medical technology company focused on developing innovative treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation [5] - The company's flagship product, Genio®, is a battery-free hypoglossal neuromodulation device designed for OSA treatment [5] Leadership Experience - John Landry brings over 20 years of financial leadership experience in the healthcare and medtech sectors, previously serving as CFO at Vapotherm Inc., where he contributed to significant revenue growth in the U.S. market [2][3] Strategic Goals - The appointment of John Landry is aimed at optimizing financial strategies and driving operational efficiencies as Nyxoah prepares Genio for commercialization in the U.S. [3] - The company is committed to building a strong leadership team to support its ambitious growth objectives [4] Regulatory Milestones - Genio® received its European CE Mark in 2019 following the successful completion of the BLAST OSA study [6] - Nyxoah has completed two successful IPOs, on Euronext Brussels in September 2020 and NASDAQ in July 2021 [6] - The company has received CE mark approval for expanding therapeutic indications to Complete Concentric Collapse (CCC) patients, which are currently contraindicated in competitors' therapies [6]

Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024 Mont-Saint-Guibert, Belgium – October 22, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. Compan ...

INSIDE INFORMATION REGULATED INFORMATION Nyxoah Raises $27 Million through its At-the-Market Offering Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus Mont-Saint-Guibert, Belgium – October 7, 2024, 11:00pm CET / 5:00pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced ...

Exhibit 99.1 Publication relating to transparency notifications September 27, 2024 REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 27, 2024, 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On September 24, 2024, Nyxoah received a transparen ...

Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliv ...

Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device FDA regulatory submission for the Company's Genio® device is complete, U.S. approval on track for the end of 2024 U.S. commercial launch, expected at the beginning of 2025, fully funded with over €85 million in new capital raised Nyxoah – NASDAQ Closing Bell Ceremony 29 août 2024 Mont-Saint-Guibert, Belgium – September 2, 2024 10:05pm CET / 4:05PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (" ...

Nyxoah S.A. (NASDAQ:NYXH) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and Investor Relations Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Suraj Kalia - Oppenheimer Edward White - H.C. Wainwright Joseph Federico - Stifel Ross Osborn - Cantor Fitzgerald David Rescott - Baird Operator Good day, everyone, and thank you for standing by. Welcome to Nyxoah Second Quarter 2024 Earnings Conference Call. [O ...

Nyxoah SA (NYXH) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -2.22%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.45, delivering no surprise. Over the last four quarters, the company has surpassed consensus E ...

Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on Tuesday, August 6, 2024, after market close. Company management will host a conference call to discuss financial resu ...

Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by strong operational execution. Scott is a passionate advocate for people and talent development. Scott graduated with the Superintendent's Award for Excellence (Star Wreath) from the United States Military Academy at West Point, NY. After serving as a Captain in the U.S. Army, Scott received his MBA from the University of Min ...